Search

Your search keyword '"Castro-Hernández, Clementina"' showing total 36 results
Start Over Author "Castro-Hernández, Clementina" Publication Year Range Last 10 years
36 results on '"Castro-Hernández, Clementina"'

1. Understanding Sociodemographic Factors among Hispanics Through a Population-Based Study on Testicular Cancer in Mexico

Author

Ríos-Rodríguez, Juan Alberto, Montalvo-Casimiro, Michel, Álvarez-López, Diego Ivar, Reynoso-Noverón, Nancy, Cuevas-Estrada, Berenice, Mendoza-Pérez, Julia, Jiménez-Ríos, Miguel A., Wegman-Ostrosky, Talia, Salcedo-Tello, Pamela, Scavuzzo, Anna, Castro-Hernández, Clementina, Herrera, Luis A., and González-Barrios, Rodrigo

Published
2025
Full Text
View/download PDF

2. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches

Author

Alarcón-Zendejas, Ana Paula, Scavuzzo, Anna, Jiménez-Ríos, Miguel A., Álvarez-Gómez, Rosa M., Montiel-Manríquez, Rogelio, Castro-Hernández, Clementina, Jiménez-Dávila, Miguel A., Pérez-Montiel, Delia, González-Barrios, Rodrigo, Jiménez-Trejo, Francisco, Arriaga-Canon, Cristian, and Herrera, Luis A.

Published
2022
Full Text
View/download PDF

3. Transcriptome Analysis Identifies GATA3-AS1 as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Author

Contreras-Espinosa, Laura, Alcaraz, Nicolás, De La Rosa-Velázquez, Inti A., Díaz-Chávez, José, Cabrera-Galeana, Paula, Rebollar-Vega, Rosa, Reynoso-Noverón, Nancy, Maldonado-Martínez, Héctor A., González-Barrios, Rodrigo, Montiel-Manríquez, Rogelio, Bautista-Sánchez, Diana, Castro-Hernández, Clementina, Alvarez-Gomez, Rosa M., Jiménez-Trejo, Francisco, Tapia-Rodríguez, Miguel, García-Gordillo, José A., Pérez-Rosas, Augusto, Bargallo-Rocha, Enrique, Arriaga-Canon, Cristian, and Herrera, Luis A.

Published
2021
Full Text
View/download PDF

4. Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma

Author

Carlos-Escalante, José Alberto, Gómez-Flores-Ramos, Liliana, Bian, Xiaopeng, Perdomo-Pantoja, Alexander, de Andrade, Kelvin César, Mejía-Pérez, Sonia Iliana, Cacho-Díaz, Bernardo, González-Barrios, Rodrigo, Reynoso-Noverón, Nancy, Soto-Reyes, Ernesto, Sánchez-Correa, Thalía Estefanía, Guerra-Calderas, Lissania, Yan, Chunhua, Chen, Qingrong, Castro-Hernández, Clementina, Vidal-Millán, Silvia, Taja-Chayeb, Lucía, Gutiérrez, Olga, Álvarez-Gómez, Rosa María, Gómez-Amador, Juan Luis, Ostrosky-Wegman, Patricia, Mohar-Betancourt, Alejandro, Herrera-Montalvo, Luis Alonso, Corona, Teresa, Meerzaman, Daoud, and Wegman-Ostrosky, Talia

Published
2021
Full Text
View/download PDF

7. The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer.

Author

González-Woge, Miguel, Contreras-Espinosa, Laura, García-Gordillo, José Antonio, Aguilar-Villanueva, Sergio, Bargallo-Rocha, Enrique, Cabrera-Galeana, Paula, Vasquez-Mata, Tania, Cervantes-López, Ximena, Vargas-Lías, Diana Sofía, Montiel-Manríquez, Rogelio, Bautista-Hinojosa, Luis, Rebollar-Vega, Rosa, Castro-Hernández, Clementina, Álvarez-Gómez, Rosa María, De La Rosa-Velázquez, Inti Alberto, Díaz-Chávez, José, Jiménez-Trejo, Francisco, Arriaga-Canon, Cristian, and Herrera, Luis Alonso

Subjects
NUCLEIC acid hybridization, GENE expression, BREAST cancer, NEOADJUVANT chemotherapy, PHENOTYPES
Abstract

lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer.

Author

Dominguez-Ortiz, Julieta, Álvarez-Gómez, Rosa M., Montiel-Manríquez, Rogelio, Cedro-Tanda, Alberto, Alcaraz, Nicolás, Castro-Hernández, Clementina, Bautista-Hinojosa, Luis, Contreras-Espinosa, Laura, Torres-Maldonado, Leda, Fragoso-Ontiveros, Verónica, Sánchez-Contreras, Yuliana, González-Barrios, Rodrigo, Fuente-Hernández, Marcela Angélica De la, Mejía-Aguayo, María de la Luz, Juárez-Figueroa, Ulises, Padua-Bracho, Alejandra, Sosa-León, Rodrigo, Obregon-Serrano, Gabriela, Vidal-Millán, Silvia, and Núñez-Martínez, Paulina María

Subjects
BRCA genes, MEXICANS, OVARIAN cancer, GENETIC transcription, KRUSKAL-Wallis Test, BREAST
Abstract

Hereditary breast and ovarian cancer (HBOC) syndrome is a genetic condition that increases the risk of breast cancer by 80% and that of ovarian cancer by 40%. The most common pathogenic variants (PVs) causing HBOC occur in the BRCA1 gene, with more than 3850 reported mutations in the gene sequence. The prevalence of specific PVs in BRCA1 has increased across populations due to the effect of founder mutations. Therefore, when a founder mutation is identified, it becomes key to improving cancer risk characterization and effective screening protocols. The only founder mutation described in the Mexican population is the deletion of exons 9 to 12 of BRCA1 (BRCA1Δ9–12), and its description focuses on the gene sequence, but no transcription profiles have been generated for individuals who carry this gene. In this study, we describe the transcription profiles of cancer patients and healthy individuals who were heterozygous for PV BRCA1Δ9–12 by analyzing the differential expression of both alleles compared with the homozygous BRCA1 control group using RT–qPCR, and we describe the isoforms produced by the BRCA1 wild-type and BRCA1Δ9–12 alleles using nanopore long-sequencing. Using the Kruskal–Wallis test, our results showed a similar transcript expression of the wild-type allele between the healthy heterozygous group and the homozygous BRCA1 control group. An association between the recurrence and increased expression of both alleles in HBOC patients was also observed. An analysis of the sequences indicated four wild-type isoforms with diagnostic potential for discerning individuals who carry the PV BRCA1Δ9–12 and identifying which of them has developed cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Bone Remodeling and Bone Structural Genes in Legg–Calvé–Perthes Disease: The OPG rs2073618 and IL-6 rs1800795 Are Associated with High Risk in Mexican Patients.

Author

Cruz-Ortíz, Blanca Lucía, Hernández-Zamora, Edgar, Reyes-Maldonado, Elba, Rodríguez-Olivas, Armando Odiseo, Rubio-Lightbourn, Julieta, Martínez-Ramírez, Celeste O., Castro-Hernández, Clementina, Lezama-Palacios, Ruth, and Casas-Avila, Leonora

Subjects
BONE remodeling, MEXICANS, INTERLEUKIN-6, IDIOPATHIC femoral necrosis, BONE growth, BLOOD coagulation factors, INTERLEUKIN-23
Abstract

Legg–Calve–Perthes disease (LCPD) is an idiopathic avascular necrosis of the pediatric femoral head. Bone remodeling and bone structural genes have the potential to contribute to the progression of LCPD when there is disequilibrium between bone resorption and bone formation. A case–control study was performed to search for associations of several common polymorphisms in the genes Receptor Activator for Nuclear Factor κappa B (RANK), Receptor Activator for Nuclear Factor κappa B Ligand (RANKL), osteoprotegerin (OPG), interleukin (IL)-6, and type 1 collagen (COL1A1) with LCPD susceptibility in Mexican children. A total of 23 children with LCPD and 46 healthy controls were genotyped for seven polymorphisms (rs3018362, rs12585014, rs2073618, rs1800795, rs1800796, rs1800012, and rs2586498) in the RANK, RANKL, OPG, IL-6, and COL1A1 genes by real-time polymerase chain reaction with TaqMan probes. The variant allele (C) of IL-6 rs1800795 was associated with increased risk of LCPD (odds ratio [OR]: 3.8, 95% confidence interval [CI]: [1.08–13.54], p = 0.033), adjusting data by body mass index (BMI) and coagulation factor V (FV), the association with increased risk remained (OR: 4.9, 95% CI: [1.14–21.04], p = 0.025). The OPG polymorphism rs2073618, specifically GC-GG carriers, was associated with a more than fourfold increased risk of developing LCPD (OR: 4.34, 95% CI: [1.04–18.12], p = 0.033) when data were adjusted by BMI-FV. There was no significant association between RANK rs3018362, RANKL rs12585014, IL-6 rs1800796, COL1A1 rs1800012, and rs2586498 polymorphisms and LCPD in a sample of Mexican children. The rs1800975 and rs2037618 polymorphisms in the IL-6 and OPG genes, respectively, are informative markers of increased risk of LCPD in Mexican children. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Understanding Sociodemographic Factors among Hispanics Through a Population-Based Study on Testicular Cancer in Mexico

Author

Ríos-Rodríguez, Juan Alberto, primary, Montalvo-Casimiro, Michel, additional, Álvarez-López, Diego Ivar, additional, Reynoso-Noverón, Nancy, additional, Cuevas-Estrada, Berenice, additional, Mendoza-Pérez, Julia, additional, Jiménez-Ríos, Miguel A., additional, Wegman-Ostrosky, Talia, additional, Salcedo-Tello, Pamela, additional, Scavuzzo, Anna, additional, Castro-Hernández, Clementina, additional, Herrera, Luis A., additional, and González-Barrios, Rodrigo, additional

Published
2023
Full Text
View/download PDF

11. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer

Author

Justo-Garrido, Montserrat, primary, López-Saavedra, Alejandro, additional, Alcaraz, Nicolás, additional, Cortés-González, Carlo C., additional, Oñate-Ocaña, Luis F., additional, Caro-Sánchez, Claudia Haydee Sarai, additional, Castro-Hernández, Clementina, additional, Arriaga-Canon, Cristian, additional, Díaz-Chávez, José, additional, and Herrera, Luis A., additional

Published
2023
Full Text
View/download PDF

14. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer

Author

Justo-Garrido, Montserrat, López-Saavedra, Alejandro, Alcaraz, Nicolás, Cortés-González, Carlo C., Oñate-Ocaña, Luis F., Caro-Sánchez, Claudia Haydee Sarai, Castro-Hernández, Clementina, Arriaga-Canon, Cristian, Díaz-Chávez, José, Herrera, Luis A., Justo-Garrido, Montserrat, López-Saavedra, Alejandro, Alcaraz, Nicolás, Cortés-González, Carlo C., Oñate-Ocaña, Luis F., Caro-Sánchez, Claudia Haydee Sarai, Castro-Hernández, Clementina, Arriaga-Canon, Cristian, Díaz-Chávez, José, and Herrera, Luis A.

Abstract

Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance., Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.

Published
2023

17. Expression of DNA Methyltransferase 3B Isoforms Is Associated with DNA Satellite 2 Hypomethylation and Clinical Prognosis in Advanced High-Grade Serous Ovarian Carcinoma

Author

Del Castillo Falconi, Victor M., primary, Díaz-Chávez, José, additional, Torres-Arciga, Karla, additional, Luna-Maldonado, Fernando, additional, Gudiño-Gomez, Adriana A., additional, Pedroza-Torres, Abraham, additional, Castro-Hernández, Clementina, additional, Cantú de León, David, additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

18. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection

Author

Arriaga-Canon, Cristian, primary, Contreras-Espinosa, Laura, additional, Rebollar-Vega, Rosa, additional, Montiel-Manríquez, Rogelio, additional, Cedro-Tanda, Alberto, additional, García-Gordillo, José Antonio, additional, Álvarez-Gómez, Rosa María, additional, Jiménez-Trejo, Francisco, additional, Castro-Hernández, Clementina, additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

19. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., Herrera, Luis A., González-Barrios, Rodrigo, Alcaraz, Nicolás, Montalvo-Casimiro, Michel, Cervera, Alejandra, Arriaga-Canon, Cristian, Munguia-Garza, Paulina, Hinojosa-Ugarte, Diego, Sobrevilla-Moreno, Nora, Torres-Arciga, Karla, Mendoza-Perez, Julia, Diaz-Chavez, José, Cortes-González, Carlo Cesar, Castro-Hernández, Clementina, Martínez-Cedillo, Jorge, Scavuzzo, Ana, Pérez-Montiel, Delia, Jiménez-Ríos, Miguel A., and Herrera, Luis A.

Abstract

Despite having a favorable response to platinum-based chemotherapies, ~15% of Testicular Germ-Cell Tumor (TGCT) patients are platinum-resistant. Mortality rates among Latin American countries have remained constant over time, which makes the study of this population of particular interest. To gain insight into this phenomenon, we conducted whole-exome sequencing, microarraybased comparative genomic hybridization, and copy number analysis of 32 tumors from a Mexican cohort, of which 18 were platinum-sensitive and 14 were platinum-resistant. We incorporated analyses of mutational burden, driver mutations, and SNV and CNV signatures. DNA breakpoints in genes were also investigated and might represent an interesting research opportunity. We observed that sensitivity to chemotherapy does not seem to be explained by any of the mutations detected. Instead, we uncovered CNVs, particularly amplifications on segment 2q11.1 as a novel variant with chemosensitivity biomarker potential. Our data shed light into understanding platinum resistance in a Latin-origin population.

Published
2022

20. Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy

Author

González-Barrios, Rodrigo, primary, Alcaraz, Nicolás, additional, Montalvo-Casimiro, Michel, additional, Cervera, Alejandra, additional, Arriaga-Canon, Cristian, additional, Munguia-Garza, Paulina, additional, Hinojosa-Ugarte, Diego, additional, Sobrevilla-Moreno, Nora, additional, Torres-Arciga, Karla, additional, Mendoza-Perez, Julia, additional, Diaz-Chavez, José, additional, Cortes-González, Carlo Cesar, additional, Castro-Hernández, Clementina, additional, Martínez-Cedillo, Jorge, additional, Scavuzzo, Ana, additional, Pérez-Montiel, Delia, additional, Jiménez-Ríos, Miguel A., additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

21. Association of Polymorphisms in Estrogen Receptor Genes (ESR1 and ESR2) with Osteoporosis and Fracture—Involvement of Comorbidities and Epistasis

Author

García-Rojas, M. Davidnia, primary, Palma-Cordero, Grecia, additional, Martínez-Ramírez, Celeste O., additional, Ponce de León-Suárez, Valeria, additional, Valdés-Flores, Margarita, additional, Castro-Hernández, Clementina, additional, Rubio-Lightbourn, Julieta, additional, Hernández-Zamora, Edgar, additional, Reyes-Maldonado, Elba, additional, Velázquez-Cruz, Rafael, additional, Barredo-Prieto, Blanca, additional, and Casas-Avila, Leonora, additional

Published
2022
Full Text
View/download PDF

22. Methylation of Subtelomeric Chromatin Modifies the Expression of the lncRNA TERRA, Disturbing Telomere Homeostasis

Author

Oliva-Rico, Diego, primary, Fabian-Morales, Eunice, additional, Cáceres-Gutiérrez, Rodrigo E., additional, Gudiño, Adriana, additional, Cisneros-Soberanis, Fernanda, additional, Dominguez, Julieta, additional, Almaraz-Rojas, Oscar, additional, Arriaga-Canon, Cristian, additional, Castro-Hernández, Clementina, additional, De la Rosa, Carlos, additional, Reyes, José L., additional, and Herrera, Luis A., additional

Published
2022
Full Text
View/download PDF

23. Large‐scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML

Author

Fabian‐Morales, Eunice, primary, Vallejo‐Escamilla, David, additional, Gudiño, Adriana, additional, Rodríguez, Alfredo, additional, González‐Barrios, Rodrigo, additional, Rodríguez Torres, Yameli L., additional, Castro Hernández, Clementina, additional, Torre‐Luján, Alfredo H., additional, Oliva‐Rico, Diego A., additional, Ornelas Guzmán, Erandhi C., additional, López Saavedra, Alejandro, additional, Frias, Sara, additional, and Herrera, Luis A., additional

Published
2021
Full Text
View/download PDF

24. Genotoxicity of Marijuana in Mono-Users

Author

Fabian-Morales, Eunice, primary, Fernández-Cáceres, Carmen, additional, Gudiño, Adriana, additional, Andonegui Elguera, Marco A., additional, Torres-Arciga, Karla, additional, Escobar Arrazola, Marco Armando, additional, Tolentino García, Laura, additional, Alfaro Mora, Yair E., additional, Oliva-Rico, Diego A., additional, Cáceres Gutiérrez, Rodrigo E., additional, Domínguez Ortíz, Julieta, additional, Castro Hernández, Clementina, additional, Herrera Montalvo, Luis A., additional, Díaz-Negrete, David Bruno, additional, and Reynoso-Noverón, Nancy, additional

Published
2021
Full Text
View/download PDF

25. Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy

Author

González-Barrios, Rodrigo, primary, Alcaraz, Nicolás, additional, Montalvo-Casimiro, Michel, additional, Cervera, Alejandra, additional, Munguia-Garza, Paulina, additional, Arriaga-Canon, Cristian, additional, Hinojosa-Ugarte, Diego, additional, Sobrevilla-Moreno, Nora, additional, Torres-Arciga, Karla, additional, Mendoza-Perez, Julia, additional, Diaz-Chavez, José, additional, Cortes, Carlo Cesar, additional, Scavuzzo, Ana, additional, Castro-Hernández, Clementina, additional, Martínez-Cedillo, Jorge, additional, Pérez-Montiel, Delia, additional, Jiménez-Ríos, Miguel, additional, and Herrera, Luis A., additional

Published
2021
Full Text
View/download PDF

26. Project Astrocytoma

Author

Carlos-Escalante, Jose Alberto, Gómez-Flores-Ramos, Liliana, Bian, Xiaopeng, Perdomo-Pantoja, Alexander, de Andrade, Kelvin César, Mejía-Pérez, Sonia, Cacho-Díaz, Bernardo, González-Barrios, Rodrigo, Reynoso-Noverón, Nancy, Soto-Reyes, Ernesto, Guerra-Calderas, Lissania, Sánchez-Correa, Thalía Estefanía, Yan, Chunhua, Chen, Qingrong, Castro-Hernández, Clementina, Vidal-Millán, Silvia, Taja-Chayeb, Lucia, Gutiérrez, Olga, Álvarez-Gómez, Rosa Maria, Gomez-Amador, Juan Luis, Ostrosky-Wegman, Patricia, Mohar-Betancourt, Alejandro, Herrera-Montalvo, Luis Alonso, Corona, Teresa, Meerzaman, Daoud, and Wegman-Ostrosky, Talia

Abstract

Here will be uploaded the VCF files used in the study

Published
2020
Full Text
View/download PDF

28. Landscape of Germline Genetic Variants in AGT, MGMT, and TP53 in Mexican Adult Patients with Astrocytoma

Author

Carlos-Escalante, José Alberto, primary, Gómez-Flores-Ramos, Liliana, additional, Bian, Xiaopeng, additional, Perdomo-Pantoja, Alexander, additional, de Andrade, Kelvin César, additional, Mejía-Pérez, Sonia Iliana, additional, Cacho-Díaz, Bernardo, additional, González-Barrios, Rodrigo, additional, Reynoso-Noverón, Nancy, additional, Soto-Reyes, Ernesto, additional, Sánchez-Correa, Thalía Estefanía, additional, Guerra-Calderas, Lissania, additional, Yan, Chunhua, additional, Chen, Qingrong, additional, Castro-Hernández, Clementina, additional, Vidal-Millán, Silvia, additional, Taja-Chayeb, Lucía, additional, Gutiérrez, Olga, additional, Álvarez-Gómez, Rosa María, additional, Gómez-Amador, Juan Luis, additional, Ostrosky-Wegman, Patricia, additional, Mohar-Betancourt, Alejandro, additional, Herrera-Montalvo, Luis Alonso, additional, Corona, Teresa, additional, Meerzaman, Daoud, additional, and Wegman-Ostrosky, Talia, additional

Published
2020
Full Text
View/download PDF

29. Large‐scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML.

Author

Fabian‐Morales, Eunice, Vallejo‐Escamilla, David, Gudiño, Adriana, Rodríguez, Alfredo, González‐Barrios, Rodrigo, Rodríguez Torres, Yameli L., Castro Hernández, Clementina, de la Torre‐Luján, Alfredo H., Oliva‐Rico, Diego A., Ornelas Guzmán, Erandhi C., López Saavedra, Alejandro, Frias, Sara, and Herrera, Luis A.

Subjects
CHIMERIC proteins, ANAPLASTIC lymphoma kinase, CHRONIC myeloid leukemia, CHROMOSOMES, MYELOPROLIFERATIVE neoplasms, PROTEIN-tyrosine kinase inhibitors, PROGNOSIS
Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm defined by the presence of t(9;22) translocation whose origin has been associated with the tridimensional genome organization. This rearrangement leads to the fusion of BCR and ABL1 genes giving rise to a chimeric protein with constitutive kinase activity. Imatinib, a tyrosine kinase inhibitor (TKI), is used as a first‐line treatment for CML, though ~40% of CML patients do not respond. Here, using structured illumination microscopy (SIM) and 3D reconstruction, we studied the 3D organization patterns of the ABL1 and BCR genes, and their chromosome territories (CTs) CT9 and CT22, in CD34+ cells from CML patients that responded or not to TKI. We found that TKI resistance in CML is associated with high levels of structural disruption of CT9 and CT22 in CD34+ cells, increased CT volumes (especially for CT22), intermingling between CT9 and CT22, and an open‐chromatin epigenetic mark in CT22. Altogether our results suggest that large‐scale disruption of CT9 and CT22 correlates with the clinical response of CML patients, which could be translated into a potential prognostic marker of response to treatment in this disease and provide novel insights into the mechanisms underlying resistance to TKI in CML. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Abstract 5176: Topological characterization of chromosome territories 9 and 22 and BCR-ABL1 genes in bone marrow CD34+ cells

Author

Fabián-Morales, Eunice, primary, Torres, Yameli Lizeth Rodríguez, additional, Escamilla, David G. Vallejo, additional, González-Barrios, Rodrigo, additional, Luján, Alfredo De La Torre, additional, López-Saavedra, Alejandro, additional, Castro-Hernández, Clementina, additional, and Montalvo, Luis A Herrera, additional

Published
2019
Full Text
View/download PDF

31. Association of the Promoter Methylation and the rs12917 Polymorphism of MGMT with Formation of DNA Bulky Adducts and the Risk of Lung Cancer in Mexican Mestizo Population

Author

Martínez-Ramírez, Ollin Celeste, primary, Pérez-Morales, Rebeca, additional, Castro-Hernández, Clementina, additional, Gonsebatt, Maria Eugenia, additional, Casas-Ávila, Leonora, additional, Valdés-Flores, Margarita, additional, Petrosyan, Pavel, additional, de León-Suárez, Valeria Ponce, additional, and Rubio, Julieta, additional

Published
2019
Full Text
View/download PDF

32. The RANKL rs12585014 polymorphism is associated with age at menarche in postmenopausal women with hip fracture

Author

Casas-Avila, Leonora, primary, Ponce de León-Suárez, Valeria, additional, Peñaloza-Espinosa, Rosenda I., additional, Cerda-Flores, Ricardo M., additional, Pérez-Ríos, Alin, additional, Martínez-Ramírez, O. Celeste, additional, Rubio-Lightbourn, Julieta, additional, Castro-Hernández, Clementina, additional, and Valdés-Flores, Margarita, additional

Published
2018
Full Text
View/download PDF

33. MAD2γ, a novel MAD2 isoform, reduces mitotic arrest and is associated with resistance in testicular germ cell tumors

Author

López-Saavedra, Alejandro, primary, Ramírez-Otero, Miguel, additional, Díaz-Chávez, José, additional, Cáceres-Gutiérrez, Rodrigo, additional, Justo-Garrido, Monserrat, additional, Andonegui, Marco A., additional, Mendoza, Julia, additional, Downie-Ruíz, Ángela, additional, Cortés-González, Carlo, additional, Reynoso, Nancy, additional, Castro-Hernández, Clementina, additional, Domínguez-Gómez, Guadalupe, additional, Santibáñez, Miguel, additional, Fabián-Morales, Eunice, additional, Pruefer, Franz, additional, Luna-Maldonado, Fernando, additional, González-Barrios, Rodrigo, additional, and Herrera, Luis A., additional

Published
2016
Full Text
View/download PDF

35. Association of a (TTTA) n microsatellite and a TCT del/ins polymorphisms in the aromatase gene ( CYP19 ) with hip fracture risk in Mexican postmenopausal women.

Author

Casas-Avila, Leonora, Valdés-Flores, Margarita, Miranda-Duarte, Antonio, Ponce de León-Suárez, Valeria, Castro-Hernández, Clementina, Rubio-Lightbourn, Julieta, and Hidalgo-Bravo, Alberto

Subjects
AROMATASE, GENETIC polymorphisms, HIP fractures, OSTEOPOROSIS, POSTMENOPAUSE
Abstract

Copyright of Gynecological Endocrinology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2015
Full Text
View/download PDF

36. Transcriptome Analysis Identifies GATA3-AS1as a Long Noncoding RNA Associated with Resistance to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients

Author

Contreras-Espinosa, Laura, Alcaraz, Nicolás, De La Rosa-Velázquez, Inti A., Díaz-Chávez, José, Cabrera-Galeana, Paula, Vega, Rosa R., Reynoso-Noveron, Nancy, Maldonado-Martínez, Héctor A., González-Barrios, Rodrigo, Montiel-Manríquez, Rogelio, Bautista-Sánchez, Diana, Castro-Hernández, Clementina, Álvarez-Gómez, Rosa M., Jiménez-Trejo, Francisco, Tapia-Rodríguez, Miguel, García-Gordillo, José, Pérez-Rosas, Augusto, Bargallo-Rocha, Enrique, Arriaga-Canon, Cristian, and Herrera, Luis A.

Abstract

Breast cancer is one of the leading causes of mortality in women worldwide, and neoadjuvant chemotherapy has emerged as an option for the management of locally advanced breast cancer. Extensive efforts have been made to identify new molecular markers to predict the response to neoadjuvant chemotherapy. Transcripts that do not encode proteins, termed long noncoding RNAs (lncRNAs), have been shown to display abnormal expression profiles in different types of cancer, but their role as biomarkers in response to neoadjuvant chemotherapy has not been extensively studied. Herein, lncRNA expression was profiled using RNA sequencing in biopsies from patients who subsequently showed either response or no response to treatment. The GATA3-AS1transcript was overexpressed in the nonresponder group and was the most stable feature when performing selection in multiple random forest models. GATA3-AS1was experimentally validated by RT-qPCR in an extended group of 68 patients. Expression analysis confirmed that GATA3-AS1is overexpressed primarily in patients who were nonresponsive to neoadjuvant chemotherapy, with a sensitivity of 92.9%, a specificity of 75.0%, and an area under the curve of approximately 0.90, as measured by receiver operating characteristic curve analysis. The statistical model was based on luminal B-like patients and adjusted by menopausal status and phenotype (odds ratio, 37.49; 95% CI, 6.74–208.42; P = 0.001); GATA3-AS1was established as an independent predictor of response. Thus, lncRNA GATA3-AS1is proposed as a potential predictive biomarker of nonresponse to neoadjuvant chemotherapy.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results